Literature DB >> 15271353

Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin.

David Jung1, Annett Rozek, Mark Okon, Robert E W Hancock.   

Abstract

Daptomycin is a cyclic anionic lipopeptide antibiotic recently approved for the treatment of complicated skin infections (Cubicin). Its function is dependent on calcium (as Ca2+). Circular dichroism spectroscopy indicated that daptomycin experienced two structural transitions: a transition upon interaction of daptomycin with Ca2+, and a further transition upon interaction with Ca2+ and the bacterial acidic phospholipid, phosphatidyl glycerol. The Ca2+-dependent insertion of daptomycin into model membranes promoted mild and more pronounced perturbations as assessed by the increase of lipid flip-flop and membrane leakage, respectively. The NMR structure of daptomycin indicated that Ca2+ induced a conformational change in daptomycin that increased its amphipathicity. These results are consistent with the hypothesis that the association of Ca2+ with daptomycin permits it to interact with bacterial membranes with effects that are similar to those of the cationic antimicrobial peptides.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271353     DOI: 10.1016/j.chembiol.2004.04.020

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  81 in total

1.  Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins.

Authors:  Joe Pogliano; Nicolas Pogliano; Jared A Silverman
Journal:  J Bacteriol       Date:  2012-06-01       Impact factor: 3.490

2.  Ubiquitous detection of gram-positive bacteria with bioorthogonal magnetofluorescent nanoparticles.

Authors:  Hyun Jung Chung; Thomas Reiner; Ghyslain Budin; Changwook Min; Monty Liong; David Issadore; Hakho Lee; Ralph Weissleder
Journal:  ACS Nano       Date:  2011-10-10       Impact factor: 15.881

3.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.

Authors:  Lisa Friedman; Jeff D Alder; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 5.  Nonribosomal peptide synthetases involved in the production of medically relevant natural products.

Authors:  Elizabeth A Felnagle; Emily E Jackson; Yolande A Chan; Angela M Podevels; Andrew D Berti; Matthew D McMahon; Michael G Thomas
Journal:  Mol Pharm       Date:  2008-01-25       Impact factor: 4.939

6.  Mechanisms of resistance to daptomycin in Enterococcus faecium.

Authors:  Clemente I Montero; Frida Stock; Patrick R Murray
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

7.  Influence of Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif.

Authors:  T Böttiger; T Schneider; B Martínez; H-G Sahl; I Wiedemann
Journal:  Appl Environ Microbiol       Date:  2009-05-08       Impact factor: 4.792

Review 8.  How nature morphs peptide scaffolds into antibiotics.

Authors:  Elizabeth M Nolan; Christopher T Walsh
Journal:  Chembiochem       Date:  2009-01-05       Impact factor: 3.164

9.  A novel synthesis of trans-unsaturated fatty acids by the Gram-positive commensal bacterium Enterococcus faecalis FA2-2.

Authors:  Tatiana Kondakova; Sneha Kumar; John E Cronan
Journal:  Chem Phys Lipids       Date:  2019-05-02       Impact factor: 3.329

Review 10.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.